IQV Price Prediction Next Week
Analysis and Insights
Technical Analysis:
IQVIA Holdings Inc. (IQV) is currently trading at $185.86 as of 2025-03-14. The stock is showing mixed signals in its technical indicators. The RSI_6 is at 46.26, indicating the stock is not in oversold territory but is below the 50 level, suggesting bearish momentum. The MACD is at -3.79, confirming the bearish trend, while the Stochastic Oscillator is at 28.84, indicating potential oversold conditions.
News Sentiment and Fundamental Analysis:
Recent news indicates that IQVIA delivered solid Q4 results, with revenue growth of 2.3% year-over-year, beating consensus estimates. The Technology & Analytics Solutions (TAS) segment performed well, growing 8.3% year-over-year, while the Research & Development Solutions (R&DS) segment saw a slight decline. Despite this, the company maintained a strong backlog and bookings ratio, suggesting resilience in its operations.
Analysts have maintained a "Strong Buy" rating on IQV, with a mean price target of $245.32, indicating a potential upside of 32.3% from current levels. Recent insider buying activity, such as the purchase of 1,275 shares by a director, also signals confidence in the stock's future performance.
Fibonacci Levels and Price Targets:
The Fibonacci levels suggest key resistance at $191.20 and $194.44, with support at $180.71 and $177.47. The stock is currently trading near the pivot level of $185.95, indicating a potential breakout above resistance if momentum builds.
Conclusion:
Based on the technical indicators and positive news sentiment, IQV is expected to reach $191 in the next trading week. The stock is likely to break above the resistance level of $191.20, driven by strong earnings and analyst optimism.
Recommendation: Buy IQV at the current price level with a target of $191.
IQV Similar Chart Price Prediction
The price of IQV is predicted to go up 1.5%, based on the high correlation periods with NEXA. The similarity of these two price pattern on the periods is 97.85%.
IQV
NEXA
Up: 1.5%Similarity: 97.85%
IQV Revenue Forecast
IQV EPS Forecast
IQV FAQs
What is IQV revenue forecast for next quarter？
What is IQV eps forecast for next quarter？
IQV VS S&P500
IQVIA's leading position in outsourced clinical trials allows it to create sticky client relationships, further honing clinical and regulatory expertise.
The merger with IMS Health provided access to an unparalleled database of patient data, which should strengthen its clinical trial offerings.
The ongoing shift to outsourced R&D should provide the CRO industry with steady growth regardless of trends in global research and development spending.
IQV Analyst's Forecast
Patrick Donnelly
Citigroup
Hold
2025-03-04
Price Target
$225 → $210
Upside
+14.4%
Citi analyst Patrick Donnelly lowered the firm's price target on Iqvia to $210 from $225 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Coming away from earnings, investor appetite for the sector "remains very light," primarily due to ongoing U.S. government pressure, the analyst tells investors in a research note. However, Citi sees pockets of the market to be constructive on, such as bioprocessing, where it believes a recovery is underway. Danaher (DHR) is the firm's top pick.
Eric Coldwell
Baird
Hold
2025-01-21
Price Target
$212 → $210
Upside
+2.1%
Jeff Garro
Stephens & Co.
Buy
2024-12-20
Price Target
$250
Upside
+26.73%
